← Leaderboards
Keith Wycoff
Planet Biotechnology, Inc.
$31,110,743
Attributed
$42,116,217
Total exposure
38
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,116,217 · 38
By mechanism
R44$18,282,390 · 6
R01$11,289,929 · 3
R43$4,472,147 · 18
R41$3,115,627 · 7
U01$2,315,307 · 1
R33$1,434,029 · 1
Top collaborators
- Sanjay Ram16 shared
- Peter A. Rice10 shared
- John A Moss5 shared
- Lloyd M Yu3 shared
- Lisa Ann Lewis2 shared
- Yi-Pin Lin2 shared
- James Maclean2 shared
- Jutamas Shaughnessy2 shared
Others in their field
Top investigators on “Plants”
- James E. Gern · University Of Wisconsin-Madison$82,846,335
- David Heimbrook · Leidos Biomedical Research, Inc.$70,964,200
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,218,842
- Paul S. Aisen · Cognition Therapeutics, Inc.$51,156,625
- David D. McManus · Univ Of Massachusetts Med Sch Worcester$40,621,016
- Bryan O Buchholz · University Of Massachusetts Lowell$40,621,016
Research focus
PlantsIn VivoProteinsBiotechnologyPlanetsAntibioticsImmunoglobulin GIn VitroInfectionProductionCostTobaccoDesignCellsVariantLeadComplementSafetyBindingAntibodiesPathogenMonoclonal AntibodiesPreventSurface
Grant awards (68)
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease$300,000
R41 · FY2025 · AI · contact PI
Bispecific antibody for topical administration to prevent gonorrhea$299,999
R43 · FY2025 · AI · contact PI
A broad spectrum anti-gonorrhea immunotherapeutic$296,920
R41 · FY2025 · AI · contact PI
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections$295,353
R43 · FY2025 · AI · contact PI
Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease$300,000
R41 · FY2024 · AI · contact PI
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections$300,000
R43 · FY2024 · AI · contact PI
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections$300,000
R41 · FY2024 · AI · contact PI
A broad spectrum anti-gonorrhea immunotherapeutic$300,000
R41 · FY2024 · AI · contact PI
Bispecific antibody for topical administration to prevent gonorrhea$299,999
R43 · FY2024 · AI · contact PI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1,000,000
R44 · FY2023 · AI · contact PI
Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections$300,000
R41 · FY2023 · AI · contact PI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$1,000,000
R44 · FY2022 · AI · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$477,355
R33 · FY2022 · AI
An immunotherapeutic to prevent gonorrhea$928,633
R44 · FY2021 · AI · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$862,755
R01 · FY2021 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$475,901
R33 · FY2021 · AI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$181,737
R41 · FY2021 · AI · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,170,759
R01 · FY2020 · AI
An immunotherapeutic to prevent gonorrhea$798,475
R44 · FY2020 · AI · contact PI
Recombinant Fc fusions for treatment of uropathogenic E. coli$486,870
R41 · FY2020 · DK · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$480,773
R33 · FY2020 · AI
Improving gene expression via Massively Parallel Synonymous Codon Variant Screening$298,634
R43 · FY2020 · GM · contact PI
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease$262,947
R41 · FY2020 · AI · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,118,405
R01 · FY2019 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$495,740
R61 · FY2019 · AI
An immunotherapeutic to prevent gonorrhea$300,000
R44 · FY2019 · AI · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,051,980
R01 · FY2018 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$523,283
R61 · FY2018 · AI
An immunoadhesin therapy for glioblastoma targeting CD97$263,999
R43 · FY2018 · CA · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,250,425
R01 · FY2017 · AI
A novel anti-gonorrhea immunotherapeutic$242,093
R41 · FY2017 · AI · contact PI
A mucosally targeted MERS-CoV vaccine produced in plants$236,488
R43 · FY2017 · AI · contact PI
A MERS-CoV Receptor Decoy$773,409
R44 · FY2016 · AI · contact PI
A MERS-CoV Receptor Decoy$801,833
R44 · FY2015 · AI · contact PI
A MERS-CoV Receptor Decoy$225,000
R43 · FY2014 · AI · contact PI
Exploiting Superinfection Exclusion To Express Polyclonal Antibodies In Plants$224,999
R43 · FY2014 · GM · contact PI
Targeted mutagenesis of plant genes by the CRISPR/Cas system$224,126
R43 · FY2014 · GM · contact PI
A Cell-Penetrating Anthrax Antitoxin$219,367
R43 · FY2014 · AI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,145,064
R01 · FY2013 · AI
Final preclinical development of an immunoadhesin therapy for inhalation anthrax$715,128
R01 · FY2013 · AI · contact PI
Chimeric IgG/A Tumor Immunotherapy$276,767
R43 · FY2013 · CA · contact PI
Phase I clinical trial of an immunoadhesin antitoxin for anthrax$187,765
R34 · FY2013 · AI · contact PI
Final preclinical development of an immunoadhesin therapy for inhalation anthrax$1,230,830
R01 · FY2012 · AI · contact PI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,166,055
R01 · FY2012 · AI
Novel Therapy for Pulmonary Anthrax$995,532
R44 · FY2012 · AI · contact PI
An immunoadhesin for treatment of hypercholesterolemia$282,629
R43 · FY2012 · HL · contact PI
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against$1,578,528
R01 · FY2011 · AI
Novel Therapy for Pulmonary Anthrax$1,000,000
R44 · FY2011 · AI · contact PI
Maximizing Expression of Immunoglobulins in Plants$286,365
R44 · FY2011 · GM
Plant-Made Nanobodies for Botulism Treatment$236,847
R43 · FY2011 · AI · contact PI
Novel Therapy for Pulmonary Anthrax$1,000,000
R44 · FY2010 · AI · contact PI
An Immunoadhesin Therapy for Inhalational Anthrax$969,948
U01 · FY2010 · AI · contact PI
Maximizing Expression of Immunoglobulins in Plants$511,596
R44 · FY2010 · GM
An Immunoadhesin Therapy for Inhalational Anthrax$1,345,359
U01 · FY2009 · AI · contact PI
Novel Therapy for Pulmonary Anthrax$203,797
R44 · FY2009 · AI · contact PI
An Immunoadhesin Therapy for Gastrointestinal Anthrax$159,096
R43 · FY2009 · AI · contact PI
Botulinum Toxin Plantibodies$1,614,009
R44 · FY2008 · AI · contact PI
Novel Therapy for Pulmonary Anthrax$827,103
R44 · FY2008 · AI · contact PI
An Anti-Cancer Immunoadhesin Made in Plants$159,450
R43 · FY2008 · CA · contact PI
Improved Method for Purification of Therapeutic Proteins from Plants$109,964
R43 · FY2008 · AI · contact PI
Botulinum Toxin Plantibodies$1,818,914
R44 · FY2007 · AI · contact PI
Novel Therapy for Pulmonary Anthrax$1,757,320
R44 · FY2007 · AI · contact PI
Optimization of Codon-Pair Usage to Maximize Protein Expression in Plants$145,410
R43 · FY2007 · GM · contact PI
Botulinum Toxin Plantibodies$1,660,566
R44 · FY2006 · AI · contact PI
Novel Therapy for Pulmonary Anthrax$1,004,838
R44 · FY2006 · AI · contact PI
Amplicon Plus for High-Level Expression of Therapeutic Proteins in Plants$145,060
R41 · FY2005 · AI
Immunotherapy for Pulmonary Anthrax$109,500
R43 · FY2003 · AI
Botulinum Toxin Plantibodies$104,520
R43 · FY2002 · AI